Vaxart (NASDAQ:VXRT – Get Free Report) and NKGen Biotech (NYSE:NKGN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.
Institutional & Insider Ownership
18.0% of Vaxart shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 2.6% of Vaxart shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Vaxart has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vaxart | 0 | 0 | 2 | 0 | 3.00 |
| NKGen Biotech | 0 | 0 | 0 | 0 | 0.00 |
Vaxart currently has a consensus price target of $3.00, indicating a potential upside of 612.25%. Given Vaxart’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Vaxart is more favorable than NKGen Biotech.
Valuation & Earnings
This table compares Vaxart and NKGen Biotech”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vaxart | $28.70 million | 3.35 | -$82.46 million | ($0.34) | -1.24 |
| NKGen Biotech | $80,000.00 | 91.75 | -$82.94 million | ($2.45) | -0.07 |
Vaxart has higher revenue and earnings than NKGen Biotech. Vaxart is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Vaxart and NKGen Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vaxart | -431.61% | -110.46% | -62.78% |
| NKGen Biotech | N/A | N/A | -479.36% |
Summary
Vaxart beats NKGen Biotech on 8 of the 14 factors compared between the two stocks.
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
About NKGen Biotech
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
